KM	Mus musculus	0.44	Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc	*IGnT B
KM	Mus musculus	0.52	NeuAcalpha(2-6)Galbeta(1-4)GlcNacbeta(1-3)Galbeta(1-4)Glc	*IGnT B
KM	Mus musculus	0.55	Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)GlcNAcbeta(1-3)Galbeta(1-4)Glc	*IGnT B
KM	Sus scrofa	0.96	pyridylaminated lacto-N-neotetraose	*
KM	Sus scrofa	2.59	UDP-N-acetyl-D-glucosamine	*
MW	Sus scrofa	76000	*	*x * 76000, SDS-PAGE under nonreducing conditions
PATH	*	Glycosphingolipid biosynthesis - lacto and neolacto series	*	*
PATH	*	i antigen and I antigen biosynthesis	*	*
PATH	*	Metabolic pathways	*	*
PATH	*	terminal O-glycans residues modification (via type 2 precursor disaccharide)	*	*
SA	Mus musculus	-999	*	*when expressed as proteins IGnT B shows higher specific activity than IGnT A; when expressed as proteins IGnT B shows higher specific activity than IGnT A
SA	Sus scrofa	0.058	*	*
SA	Rattus norvegicus	0.084	*	*
